



Diagnosis and Treatment of Allergic Diseases Group

Publications: 49
Q1: 32



RESEARCH ACTIVITY

■ Doctoral theses

Gómez Traseira C. Estudio en viuda real de las características clínicas, analíticas y de manejo terapéutico de pacientes con angioedema hereditario por déficit del inhibidor de la C1 esterasa (AEH-C1-INH) [dissertation]. Madrid: UAM: 2021(19/09/2021).

Director: Caballero Molina MT.

■ Publications


- Almonacid C, Blanco-Aparicio M, Domínguez-Ortega J, Giner J, Molina J, Plaza V. Teleconsultation in the follow-up of the asthma patient. Lessons after COVID-19. Arch Bronconeumol. 2021; 57: 13-4. Editorial Material. IF: 6.333; Q1
- Barranco P, Palao P, Ruiz I, Domínguez-Ortega J, Vila-Nadal G, Pola B, Quirce S. Relationship between IGE-mediated sensitization to staphylococcus aureus enterotoxin B, asthma severity, and atopy. J Invest Allerg Clin. 2021; 31(2): 170-3. Editorial Material. IF: 8.185; Q1

- Bernstein JA, Bouillet L, Caballero T, Staevska M. Hormonal effects on urticaria and angioedema conditions. J Allergy Clin Immunol Pract. 2021; 9(6): 2209-19. Review. IF: 11.022; Q1
- Betancourt A, Zapatero A, Pola-Bibian B, Domínguez-Ortega J. Impact of short-term exposure to below recommended PM10 pollution levels on asthma exacerbations. J Invest Allerg Clin. 2021; 31(5): 439-40. Editorial Material. IF: 8.185; Q1
- Bork K, Anderson JT, Caballero T, Craig T, Johnston DT, Li HH, Longhurst HJ, Radojicic C, Riedl MA. Assessment and management of disease

- burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021; 17(1): 40. Review. IF: 3.373; Q3
- Brix ATH, Boysen HB, Weller K, Caballero T, Bygum A. Patient-reported outcome measures for angioedema: A literature review. Acta Derm-Venereol. 2021; 101: adv00456. Review. IF: 3.875; Q2
- Caballero ML, Domínguez-Ortega J, Nin-Valencia AR, Sánchez-Ocando H, Barranco P. Eosinophil count could be more sensitive in induced



- sputum than in peripheral blood for phenotyping of patients with severe eosinophilic asthma. *J Invest Allerg Clin.* 2021; 31(4): 360-1. Letter. IF: 8.185; Q1
- Caballero ML, Krantz MS, Quirce S, Phillips EJ, Stone CA. Hidden dangers: recognizing excipients as potential causes of drug and vaccine hypersensitivity reactions. *J Allergy Clin Immunol Pract.* 2021; 9(8): 2968-82. Review. IF: 11.022; Q1
 - Caballero ML, Quirce S. Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of currently authorized COVID-19 vaccines. *J Invest Allerg Clin.* 2021; 31(1): 92-3. Letter. IF: 8.185; Q1
 - Caballero T. Treatment of hereditary angioedema. *J Invest Allerg Clin.* 2021; 31(1): 1-16. Review. IF: 8.185; Q1
 - Corvillo F, González-Sánchez L, López-Lera A, Arjona E, Ceccarini G, Santini F, Araujo-Vilar D, Brown RJ, Villarroya J, Villarroya F, de Cordoba SR, Caballero T, Nozal P, López-Trascasa M. Complement factor D (adipsin) levels are elevated in acquired partial lipodystrophy (Barraquer-Simons syndrome). *Int J Mol Sci.* 2021; 22(12): 6608. Article. IF: 6.208; Q1
 - Couto M, Bernard A, Delgado L, Drobnic F, Kuroski M, Moreira A, Rodrigues-Alves R, Rukhadze M, Seys S, Wiszniewska M, Quirce S. Health effects of exposure to chlorination by-products in swimming pools. *Allergy.* 2021; 76(11): 3257-75. Article. IF: 14.71; D1
 - Dafaue L, Romero D, Carpio C, Barga P, Quirce S, Villasante C, Bravo MF, Álvarez-Sala R. Psychodemographic profile in severe asthma and effect of emotional mood disorders and hyperventilation syndrome on quality of life. *BMC Psychol.* 2021; 9(1): 3. Article. IF: 2.588; Q2
 - de Llano LAP, Gancedo SQ, Moral VP. Treatment of moderate-severe asthma: an alternative strategy to the guidelines recommendations. *Arch Bronconeumol.* 2021; 57(4): 243-5. Editorial Material. IF: 6.333; Q1
 - de Llano LP, Davila I, Martínez-Moragon E, Domínguez-Ortega J, Almonacid C, Colas C, García-Rivero JL, Carmona L, de Yébenes MJG, Cosío BG. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids, symptoms score. *J Allergy Clin Immunol Pract.* 2021; 9(7): 2725-31. Article. IF: 11.022; Q1
 - Delgado J, Dávila IJ, Domínguez-Ortega J. Clinical recommendations for the management of biological treatments in severe asthma patients: a consensus statement. *J Invest Allerg Clin.* 2021; 31(1): 36-43. Review. IF: 8.185; Q1
 - Esteban-Gorgojo I, Gorgojo MP, Sastre J, Quirce S. Food allergy as an asthma comorbidity in children and adolescents: a practical approach through a real-world study. *Allergol Immunopath.* 2021; 49(1): 68-78. Article. IF: 2.094; Q4
 - Farkas H, Reshef A, Caballero T, López MCO, Kessel A, Vardi M, Hao JM, Aberer W. Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. *Pediatr Allerg Immun-Uk.* 2021; 32(6): 1392-96. Letter. IF: 5.464; D1
 - Forjaz MJ, Ayala A, Caminoa M, Prior N, Pérez-Fernández E, Caballero T. HAE-AS: A specific disease activity scale for hereditary angioedema with c1-inhibitor deficiency. *J Invest Allerg Clin.* 2021; 31(3): 246-52. Article. IF: 8.185; Q1
 - Guilarte M, Sala-Cunill A, Baeza ML, Cabañas R, Hernández MD, Ibanez E, de Larramendi CH, Leonart R, Lobera T, Marques L, Pedro BSD, Botha J, Andresen I, Caballero T. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain. *Allergy Asthma Clin Immunol.* 2021; 17(1): 137. Article. IF: 3.373; Q3
 - Lee EY, Hsieh J, Borici-Mazi R, Caballero T, Kananani A, Lacuesta G, McCusker C, Waserman S, Betschel S. Quality of life in patients with hereditary angioedema in Canada. *Ann Allerg Asthma Im.* 2021; 126(4): 394-400 Article. IF: 6.248; Q2
 - Loli-Ausejo D, de Abreu JMG, Fiandor A, Cabañas R, Domínguez-Ortega F, Caballero ML, Lluch-Bernal M, García-Panto CR, Núñez MC, Quirce S. Allergic reactions after administration of Pfizer-BioNTech COVID-19 vaccine to health care workers at a tertiary hospital. *J Invest Allerg Clin.* 2021; 31(6): 507-8. Editorial Material. IF: 8.185; Q1
 - Loli-Ausejo D, López-Lera A, Drouet C, Lluncor M, Phillips-Angles E, Pedrosa M, Cabanas R, Caballero T. In search of an association between genotype and phenotype in hereditary angioedema due to C1-INH deficiency. *Clin Rev Allerg Immu.* 2021; 61(1): 1-14. Article. IF: 10.817; Q1
 - Loli-Ausejo D, Pedrosa M, Rodríguez-Pérez R, Hurtado JL, Pérez-Tavarez R, Gasset M. Fish transformations and allergenicity. *Rev Esp Nutr Hum Diet.* 2021; 25: 61-2. Article. Not Indexed
 - Loli-Ausejo D, Vilchez-Sánchez F, Cabanas R, Fiandor A, Lluch-Bernal M, González-Munoz M, Domínguez-Ortega J. Basophil activation test in the diagnosis of hypersensitivity reactions to quinolones in a real-life setting. *Clin Exp Allergy.* 2021; 51(3): 503-7. Letter. IF: 5.401; Q2
 - López-Gálvez R, de la Morena-Barrio ME, Minoño A, Pathak M, Marcos C, Emsley J, Caballero T, López-Trascasa M, Vicente V, Corral J, López-Lera A. Thrombin in the activation of the fluid contact phase in patients with hereditary angioedema carrying the F12 P.Thr309Lys variant. *Clin Rev Allerg Immu.* 2021; 60(3): 357-68. Article. IF: 10.817; Q1
 - Lumry WR, Zuraw B, Cicardi M, Craig T, Anderson J, Banerji A, Bernstein JA, Caballero T, Farkas H, Gower RG, Keith PK, Levy DS, Li HH, Magerl M, Manning M, Riedl MA, Lawo JP, Prusty S, Machnig T, Longhurst H. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. *Orphanet J Rare Dis.* 2021; 16(1): 86. Article. IF: 4.307; Q2
 - Marqués-Mejías MA, Entrala A, Cabanas R, Caballero T. Mediastinal angioedema: A rare manifestation of hereditary angioedema. *J Allergy Clin Immunol Pract.* 2021; 9(1): 477-8. Editorial Material. IF: 11.022; Q1
 - Maurer M, Aygoren-Pursun E, Banerji A, Bernstein JA, Boysen HB, Busse PJ, Bygum A, Caballero T, Castaldo AJ, Christiansen SC, Craig T, Farkas H, Grumach AS, Hide M, Katelaris CH, Li HH, Longhurst H, Lumry WR, Magerl M, Martínez-Saguer I, Riedl MA, Zhi YX, Zuraw B. Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. *J Allergy Clin Immun.* 2021; 148(6): 1526-32. Article. IF: 14.29; D1
 - Maurer M, Caballero T, Aberer W, Zanichelli A, Bouillet L, Bygum A, Grumach AS, Botha J, Andresen I, Longhurst HJ. Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey. *J Eur Acad Dermatol.* 2021; 35(12): 2421-30. Article. IF: 9.228; D1
 - Mígueres N, Vandenaspl O, Suojalehto H, Walusiak-Skorupa J, Muñoz X, Sastre J, Merget R, Moscato G, Quirce S, Meyer N, Godet J, de Blay F. Phenotypes of occupational asthma defined with induced sputum after specific inhalation challenge. *Rev Fr Allergol.* 2021; 61(4): 223-5. Article. IF: 0.254; Q4
 - Molina-París J, Trigueros JA, Gómez-Sáenz JT, Puente-Maestu L, Julia B, Domínguez-Ortega J. Perceptions of family doctors, pulmonologists and allergists on the approach to patients with chronic cough. Results of an anonymous survey. *Semerger.* 2021; 47(6): 376-84. Article. Not Indexed
 - Nunes FL, Ferriani MPL, Moreno AS, Langer SS, Maia LSM, Ferraro MF, Sarti W, de Bessa J, Cunha D, Suffritti C, Dias MM, Januario YC, daSilva LLP, Aragon DC, Caballero T, Arruda LK. Decreasing attacks and improving quality of life through a systematic management program for patients with hereditary angioedema. *Int Arch Allergy Imm.* 2021; 182(8): 697-708. Article. IF: 3.767; Q3
 - Olaguibel JM, Alobid I, Puebla A, Crespo-Lessmann A, Ortega D, García-Río F, Izquierdo-Domínguez A, Mollol J, Plaza V, Quirce S, Rojas-Lechuga MJ, Valverde-Monge M, Sastre J. Functional examination of the upper and lower airways in asthma and respiratory allergic diseases: considerations in the post-SARS-CoV-2 era. *J Invest Allerg Clin.* 2021; 31(1): 17-35. Review. IF: 8.185; Q1
 - Pedrosa M, Loli-Ausejo D, García-Lozano JR, Fiandor A, Lluch-Bernal M, Hurtado JL, Domínguez-Ortega J, Quirce S, Gasset M, Rodríguez-Pérez R. The burden of allergens in surimi-based products diminishes with industrial processing. *J Invest Allerg Clin.* 2021; 31(5): 443-5. Editorial Material. IF: 8.185; Q1
 - Pérez-Tavárez R, Moreno HM, Borderías J, Loli-Ausejo D, Pedrosa M, Hurtado JL, Rodríguez-Pérez R, Gasset M. Fish muscle processing into seafood products reduces f3-parvalbumin allergenicity. *Food Chem.* 2021; 364: 130308. Article. IF: 9.231; D1
 - Pfeiffer S, Sandler P, Raith M, Pascal M, Muñoz-Cano RM, San Bartolome C, Nobauer K, Quirce S, Razzazi-Fazeli E, Focke-Tejkl M, Sterflinger K, Swoboda I. Identification of Ulocladium chartarum as an important indoor allergen source. *Allergy.* 2021; 76(10): 3202-6. Letter. IF: 14.71; D1
 - Plaza V, Trigueros JA, Cisneros C, Domínguez-Ortega J, Cimbollek S, Fernández S, Hernández J, López JD, Ojangueren I, Padilla A, Pallares A, Sánchez-Toril FJ, Torrego A, Urrutia I, Quirce S. The importance of small airway dysfunction in asthma: The GEMA-FORUM III task force. *J Invest Allerg Clin.* 2021; 31(5): 433-6. Editorial Material. IF: 8.185; Q1
 - Puente-Maestu L, Molina-París J, Trigueros JA, Gómez-Sáenz JT, Cea-Calvo L, Fernández S, Sánchez-Jareno M, Domínguez-Ortega J. A Survey of physicians' perception of the use and effectiveness of diagnostic and therapeutic procedures in chronic cough patients. *Lung.* 2021;



- 199(5): 507-15. Article. IF: 3.777; Q3
- Quirce S, Domínguez-Ortega J, Luna JA. Novel approaches in occupational asthma diagnosis and management. *Curr Opin Pulm Med*. 2021; 27(1): 9-14. Review. IF: 2.868; Q4
 - Rial MJ, Álvarez-Puebla MJ, Arismendi E, Caballero ML, Canas JA, Cruz MJ, González-Barcala FJ, Luna JA, Martínez-Rivera C, Mullol J, Muñoz X, Olaguibel JM, Picado C, Plaza V, Quirce S, Romero-Mesones C, Salgado FJ, Sastre B, Soto-Retes L, Valero A, Valverde M, Sastre J, del Pozo V. Clinical and inflammatory characteristics of patients with asthma in the Spanish MEGA project cohort. *Clin Transl Allergy*. 2021; 11(1): e12001. Article. IF: 5.657; Q2
 - Rial MJ, Valverde M, del Pozo V, González-Barcala FJ, Martínez-Rivera C, Muñoz X, Olaguibel JM, Plaza V, Curto E, Quirce S, Barranco P, Domínguez-Ortega J, Mullol J, Picado C, Valero A, Bobolea I, Arismendi E, Ribo P, Sastre J. Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak. *J Allergy Clin Immunol Pract*. 2021; 9(1): 487-9. Letter. IF: 11.022; Q1
 - Sánchez CA, Moreno CM, Gancedo SQ, Sánchez-Herrero MG, Gutiérrez FJA, Conejero DB, Cardona V, Soriano JB. PAGE Study: Summary of a study protocol to estimate the prevalence of severe asthma in Spain using big data methods. *J Invest Allerg Clin*. 2021; 31(4): 308-15. Article. IF: 8.185; Q1
 - Sastre J, Santiago V, Lacomba M, Quirce S, Pan V, González D, Rivera JMO, Jaen MJT, Vázquez R, Amerigo A, Fernández O. SEAIC specialty forum: analysis of the current situation of allergology in Spain and outlook for the future. *J Invest Allerg Clin*. 2021; 31(2): 120-31. Review. IF: 8.185; Q1
 - Sigurdardottir ST, Jonasson K, Clausen M, Bjornsdottir KL, Sigurdardottir SE, Roberts G, Grimshaw K, Papadopoulos NG, Xepapadaki P, Fiandor A, Quirce S, Sprickkelman AB, Hulshof L, Kowalski ML, Kurowski M, Dubakiene R, Rudzeviciene O, Bellach J, Yurek S, Reich A, Erhard SM, Couch P, Rivas MF, van Ree R, Mills C, Grabenhenrich L, Beyrer K, Keil T. Prevalence and early-life risk factors of school-age allergic multimorbidity: The EuroPrevall-iFAAM birth cohort. *Allergy*. 2021; 76(9): 2855-65. Article. IF: 14.71; D1
 - Tabar AI, Delgado J, González-Mancebo E, Arroabarren E, Retes LS, Domínguez-Ortega J. Recent advances in allergen-specific immunotherapy as treatment for allergic asthma: a practical overview. *Int Arch Allergy Imm*. 2021;

- 182(6): 496-514. Review. IF: 3.767; Q3
- Vila-Nadal G, Román AF, Revuelto RH, Hernández-Maraver D, Fuentes AEK, García ER, Moreno RC. Efficacy of therapeutic plasma exchange in severe immune hemolytic anemia induced by a carboplatin desensitization procedure. *J Invest Allerg Clin*. 2021; 31(2): 178-9. Editorial Material. IF: 8.185; Q1
 - Vilchez-Sánchez F, Tomas-Pérez M, Sánchez-Jareño M, Loli-Ausejo D, Quirce S, Domínguez-Ortega J. Allergic sensitization profiles among the foreign-born population in the north of Madrid. *Eur Ann Allergy Clin Immunol*. 2021; 53(1): 23-28. Article. Not Indexed
 - Wiszniewska M, Dellis P, van Kampen V, Suojalehto H, Munoz X, Walusiak-Skorupa J, Lindstrom I, Merget R, Romero-Mesones C, Sastre J, Quirce S, Mason P, Riffart C, Godet J, de Blay F, Vandemplas O. Characterization of occupational eosinophilic bronchitis in a multicenter cohort of subjects with work-related asthma symptoms. *J Allergy Clin Immunol Pract*. 2021; 9(2): 937-44. Article. IF: 11.022; Q1

■ Research projects

Caballero Molina MT. Development and trans-cultural validation of an international specific questionnaire (IHAE-QOL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and quality of life study (DTV-IHAE-QOL). *Hereditary Angio-Edema In*. 2009-Ongoing.

Management centre: FIBHULP

Caballero Molina MT. Estudio de las características clínicas y fisiopatológicas del angioedema sin habones (PI19/01434). *ISCI*. 2020-2022.

Management centre: FIBHULP

Caballero Molina MT. Impacto humanístico y económico del angioedema hereditario en España. *Estudio Impactaeh*. *Shire International GmbH*. 2021-Ongoing.

Management centre: FIBHULP

Domínguez Ortega FJ. Asesoramiento para el diseño del estudio clínico Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinoconjuntivitis por alergia frente al polen gramíneas. *Inmunotek*. 2015-Ongoing.

Management centre: FIBHULP

Domínguez Ortega FJ. Estudio de coste-efectividad de mepolizumab en pacientes con asma grave no controlada en condiciones de vida-real. *Glaxosmithkline S. A.* 2021-Ongoing.

Management centre: FIBHULP

Quirce Gancedo SE. Relación entre asma y obesidad en la población española mayor o igual a 18 años. *Novartis Farmacéutica S. A.* 2009-Ongoing.

Management centre: FIBHULP

Rodríguez Pérez MR. Contrato garantía juvenil técnico laboratorio (PEJ2019_TL/BMD_12199). *CM*. 2020-2021.

Management centre: FIBHULP

Rodríguez Pérez MR. Evaluación de la capacidad alergénica de productos alimentarios mediante test de activación de basófilos y sensibilización cutánea con alimentos. *Angulas Aguinaga S. A. U.* 2018-Ongoing.

Management centre: FIBHULP

Tomás Pérez M. Efectividad de la inmunoterapia sublingual de ltp (slit melocoton) en pacientes con alergia a melocoton y otros vegetales por sensibilización a ltp en condiciones de práctica clínica habitual. *Alk-Abello S.A.* 2020-Ongoing.

Management centre: FIBHULP

■ Cibers & Retics

Caballero Molina MT. Centro de Investigación Biomédica en Red de Enfermedades Raras. (CB06/07/1033). *ISCI*. (31/12/2022).

Management centre: FIBHULP

■ Clinical trials

Caballero Molina, MT. Estudio abierto para evaluar la eficacia y la seguridad a largo plazo de lanadelumab para la prevención contra las crisis agudas de angioedema no histaminérgico con inhibidor de c1 (c1-inh) normal.

Type: Clinical Trials, phase III.

HULP code: 5798 TAK-743-3001.

Sponsored by: Takeda Development Center Americas.

Signed date: 31/05/2021

Caballero Molina, MT. Estudio en fase III, multicéntrico, aleatorizado, controlado con placebo, doble ciego para evaluar la eficacia y la seguridad de lanadelumab para la prevención contra las crisis agudas de angioedema no histaminérgico con inhibidor de c1 (c1-inh) normal y angioedema adquirido (aea) debido a déficit de c1-inh.

Type: Clinical Trials, phase III.

HULP code: Appendix 1 5550.


Sponsored by: Dyax Corp.

Signed date: 13/04/2021

Caballero Molina, MT. Estudio multicéntrico, prospectivo, no intervencionista de tres años de duración para evaluar la eficacia a largo plazo de lanadelumab en la práctica clínica (enable).

Type: Estudios, phase EPA-OD.

HULP code: PI-4704 TAK-



743(SHP643)-402.

Sponsored by: Takeda Development Center Americas.

Signed date: 28/04/2021

Domínguez Ortega, FJ. Estudio de validación transversal de las versiones adaptadas localmente del cuestionario sobre el deterioro y el riesgo del asma (airq) como herramienta que identifica a pacientes con asma en riesgo de resultados adversos por asma no controlada en Alemania y España.

Type: Estudios, phase EPA-SP.

HULP code: PI-4846 AIRQ.

Sponsored by: Astrazeneca Farmaceutica Spain, S.A.

Signed date: 20/09/2021

Domínguez Ortega, FJ. Identificación de biomarcadores inmunológicos en pacientes alérgicos.

Type: Estudios No EPA.

HULP code: PI-4583 LET-INM-2020.

Sponsored by: Laboratorios Leti, S.L.

Signed date: 04/06/2021

Domínguez Ortega, FJ. Pilot study for validation of the consensus protocol developed by scientific societies (semas, separ, and seaic) in real-life conditions in two Spanish hospitals: the asmanet project.

Type: Estudios No EPA.

HULP code: PI-5056 ESR-20-20897.

Sponsored by: Instituto De Estudios Ciencias Salud Castilla Instituto De Estudios Ciencias.

Signed date: 22/12/2021

Domínguez Ortega, FJ. Pilot study for validation of the consensus protocol developed by scientific societies (semas, se-

par, and seaic) in real-life conditions in two Spanish hospitals: the asmanet project.

Type: Estudios No EPA.

HULP code: PI-5056 ASMANET- ESR-20-2089.

Sponsored by: Instituto De Estudios Ciencias Salud Castilla Instituto De Estudios Ciencias.

Signed date: 22/12/2021

Domínguez Ortega, FJ. Prime. estudio observacional prospectivo multicéntrico en varios países sobre patrones de atención de pacientes asmáticos leves.

Type: Estudios, phase EPA-SP.

HULP code: PI-4591 CHI-SAL-2020-01.

Sponsored by: Chiesi Farmaceutici S.P.A.

Signed date: 20/05/2021

Lluch Bernal, MM. Proyecto de colaboración estudio de reactividad cruzada entre cupresáceas y especies relacionadas.

Type: Estudios No EPA.

HULP code: PI-4783 PI 39/21.

Sponsored by: Alk-Abello, S.A.

Signed date: 20/05/2021

Quirce Gancedo, SE. Estudio observacional prospectivo para evaluar la seguridad y la efectividad de la inmunoterapia con un alérgico de polen de olivo y gramíneas en pacientes con asma alérgica estacional. estudio gol.

Type: Estudios, phase EPA-SP.

HULP code: PI-4707 ALLOLE-2020-01.

Sponsored by: Allergy Therapeutics Iberica Slu.

Signed date: 14/10/2021

Quirce Gancedo, SE. Registro alergodato.

Type: Estudios, phase EPA-SP.

HULP code: PI-4784 SEA-

OMA-2020-01.

Sponsored by: Fundación De La Sociedad Española De Alergología E Inmunología Clínica (Seac).

Signed date: 27/05/2021

Tomás Pérez, M. Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a gramíneas y cupresáceas.

Type: Clinical Trials, phase II.

HULP code: 5869 DMV02-SIT-026.

Sponsored by: Inmunotek.

Signed date: 29/04/2021

Tomás Pérez, M. Ensayo clínico de eficacia y seguridad, prospectivo, multicéntrico, aleatorizado, doble ciego controlado con placebo, con inmunoterapia subcutánea en pacientes con rinitis/rinoconjuntivitis con o sin asma de leve a moderada sensibilizados a gramíneas y olivo.

Type: Clinical Trials, phase II.

HULP code: 5883 DMV03-SIT-027.

Sponsored by: Inmunotek.

Signed date: 19/05/2021

Tomás Pérez, M. Estudio de fase III, multicéntrico, internacional, aleatorizado, doble ciego, controlado con placebo, de inducción y mantenimiento para evaluar la eficacia y la seguridad de CC-93538 en sujetos adultos y adolescentes con esofagitis eosinofílica.

Type: Clinical Trials, phase III.

HULP code: 5832 CC-93538-EE-001.

Sponsored by: Celgene International li -Sarl.

Signed date: 26/04/2021c

Patents and trademarks

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE

Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.

del Pozo Abejón V, Sastre Domínguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.